Clinical Trial Update: Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating maintenance belantamab mafodotin after BCMA-directed CAR T-cell therapy in relapsed or refractory multiple myeloma was terminated, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Refractory Multiple Myeloma, Relapse Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2025-01-28